State of the art biological therapies in pancreatic cancer

doi:10.4251/wjgo.v8.i1.55

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8198)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

582

WORD

349

HTML

4448

Figures (1-1)

279

Tables (1-3)

248

Sum=5906

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

898

Download

1394

Sum=2292

Jan 15, 2016 (publication date) through Feb 4, 2025

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jan 15, 2016; 8(1): 55-66
Published online Jan 15, 2016. doi: 10.4251/wjgo.v8.i1.55

Table 3 Principal ongoing trials involving targeted therapy in pancreatic cancer

ClinicalTrials.gov identifier	Agent	Target	Status
NCT01728818	Afatinib	EGFR signaling	Recruiting
NCT01659502	TL-118	Angiogenesis	Not yet recruiting
NCT01621243	Necuparanib	Angiogenesis	Recruiting
NCT01088815	Vismodegib	Hedgehog signaling	Recruiting
NCT01096732	Vismodegib	Hedgehog signaling	Terminated
NCT01431794	LDE-225	Hedgehog signaling	Recruiting
NCT00515866	KU-0059436	PARP inhibitor	Completed
NCT01585805	Veliparib	PARP inhibitor	Recruiting
NCT01571024	BKM120	mTOR and PI3K/Akt pathway	Recruiting
NCT01028495	RX-0201	mTOR and PI3K/Akt pathway	Completed
NCT01337765	BEZ235 + MEK162	mTOR and PI3K/Akt pathway	Completed
NCT00560963	Everolimus	mTOR pathway	Completed
NCT00075647	Temsirolimus	mTOR pathway	Completed
NCT01839487	PEGPH20	Tumor stroma	Recruiting

EGFR: Epidermal growth factor receptor; mTOR: Mammalian target of rapamycin.

Citation: Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66
URL: https://www.wjgnet.com/1948-5204/full/v8/i1/55.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i1.55